Knight Adds New Dimension to 3D Signatures Partnership

Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it invested $180,000 in 3D Signatures Inc. (TSX VENTURE:DXD) (“3DS”) as part of a brokered private placement of approximately $3.9 million. As consideration, Knight received 240,000 common shares of 3DS and warrants to purchase an additional 240,000 shares of 3DS at an exercise price of $0.92 with an expiry date of December 16, 2018, subject to an acceleration clause.
Earlier this year, Knight invested $1 million in 3DS and entered into both an exclusive license and distribution agreement for the territories of Canada, Israel, Russia and CIS, Sub-Saharan Africa and the Caribbean, and an advisory services agreement with 3DS.
Following the private placement, Knight owns approximately 6% of 3DS’ outstanding common shares.
“We are happy to support our partner 3D Signatures in its latest financing round which provides capital to advance the development of its novel diagnostic and prognostic technologies,” said Jonathan Ross Goodman, CEO of Knight.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com.
About 3D Signatures Inc.
3D Signatures Inc. is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the company’s new website at www.3dsignatures.com.
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.